Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment
Despite advances in therapy, metastatic castration-resistant prostate cancer (mCRPC) remains a deadly disease with poor long-term survival. Traditionally, docetaxel-based chemotherapy has been considered as a mainstay of treatment in patients progressing on androgen deprivation therapy (ADT). Management of mCRPC has significantly evolved with the introduction of cabazitaxel, abiraterone acetate, enzalutamide, and 223-radium dichloride, which are all associated with improved overall survival (OS) (Crawford et al., 2015) but, unfortunately, only limited data are available on the optimal sequence of newer agents in mCRPC (Attard et al., 2016).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco, Andrea Sbrana, Erika Coppi, Luca Galli, Sergio Bracarda, Daniele Santini, Romano Danesi Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hematology | Prostate Cancer | Taxotere